VSee Health Reports 40% Revenue Growth to $14.6M, Cuts Expenses 76%
VSee Health's 2025 revenue rose 40% year-over-year to $14.6 million while gross margin edged up 2% to $7.36 million and operating expenses plunged 76%. Cash and equivalents surged to $5.27 million, bolstered by debt-to-equity conversions, as large $10 million-per-year IDN contracts begin rolling out.
1. 2025 Financial Performance
VSee Health closed 2025 with $14.62 million in revenue, a 40% increase over 2024, and a gross margin of $7.36 million, up 2% year-over-year. Operating expenses fell 76%, significantly narrowing the company's net loss and improving overall margins.
2. Major Contracts and Government Approvals
Revenue growth was driven by multi-year agreements with large integrated delivery networks, including a $10 million-per-year contract signed in early 2025. These deals began generating meaningful revenue in the second half, with rollouts across up to 20 states, and the company secured FedRAMP High authorization for expanded federal healthcare projects.
3. Expense Cuts and Balance Sheet Strengthening
To bolster liquidity, VSee executed multiple debt-to-equity conversions, boosting cash and cash equivalents to $5.27 million at year-end from $0.33 million. The executive team streamlined legal, accounting and integration costs tied to the IPO process, setting a foundation for sustained lower operating expenses.
4. 2026 Outlook and Strategy
Entering 2026 with a fully integrated digital-to-physical care platform and scalable AI telehealth infrastructure, VSee Health is targeting hybrid care market growth through contract renewals and new enterprise wins. Management remains focused on achieving sustainable profitability and long-term shareholder value.